Vertex Pharmaceuticals (VRTX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Commercial performance and pipeline updates

• Q2 results showed strong performance, leading to raised guidance to $10.65–$10.85 billion in product revenues, reflecting 9% growth at midpoint.

• Two NDA filings accepted under priority review: vanzacaftor triple for CF (PDUFA Jan 2, 2025) and suzetrigine for acute pain (PDUFA Jan 30, 2025).

• Accelerated timelines for phase II LSR pain study, with results expected by year-end.

• VX-880 Type 1 diabetes cell therapy completed first cohort enrollment; expanded to 37 patients.

• Povetacicept phase III in IgAN initiated post-Alpine acquisition.

Pain franchise strategy and market approach

• Pain portfolio targets both acute and chronic pain, with suzetrigine as a selective NaV1.8 inhibitor aiming for non-addictive relief.

• Multi-billion dollar market potential seen in both acute (80M patients) and chronic (10M patients) pain segments.

• Next-gen VX-993 in clinic, with IV formulation and potential for combination with NaV1.7 inhibitor.

• Field force hired and focused on high-volume discharge procedures for faster uptake.

• Payer and PBM engagement ongoing, with positive early feedback on non-addictive pain therapies.

Clinical development and regulatory milestones

• Suzetrigine PDUFA date set for January 2025; FDA does not currently plan an AdCom.

• Acute pain program seeks broad label, focusing on high-volume procedures and discharge segment.

• Phase II LSR study results expected by year-end; phase III in diabetic peripheral neuropathy underway.

• VX-993 advancing in both acute and peripheral neuropathic pain studies.